SCHEMBL6833685

SCHEMBL6833685

CC1(O)C(O)C(CO)OC1n1cc(C(N)=O)c(=O)c2c(=O)[nH]cnc21

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 8/20 0.46
ADA P00813 1/20 0.39
ADORA3 P0DMS8 9/20 0.37
ADORA1 P30542 6/20 0.37
ADORA2B P29275 4/20 0.37
ADK P55263 1/20 0.36
ALOX15 P16050 1/20 0.35
MAPT P10636 2/20 0.34
NPC1 O15118 1/20 0.34
GALR3 O60755 1/20 0.34
S1PR4 O95977 1/20 0.34
ALDH1A1 P00352 1/20 0.34
S1PR1 P21453 1/20 0.34
HTT P42858 1/20 0.34
RAB9A P51151 1/20 0.34
PAX8 Q06710 1/20 0.34
PDE4D Q08499 1/20 0.33
PDE3A Q14432 1/20 0.33
SLC29A1 Q99808 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6833725 0.88 ADORA2A (0.46) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL6379675 0.86 ADORA2A (0.58) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL6382950 0.86 ADORA2A (0.58) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL6838191 0.83 ADORA2A (0.47) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL6379623 0.82 ADORA2A (0.46) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL6838481 0.82 ADORA2A (0.39) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL6383362 0.82 ADORA2A (0.39) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL12031305 0.81 ADORA2A (0.62) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL14470815 0.81 ADORA2A (0.62) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL1738024 0.81 ADORA2A (0.62) ADORA2AADAADORA3ADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063658-A1 Nucleoside derivatives for treating hepatitis C virus infection GENELABS TECHNOLOGIES, INC. 2004-04-01 US claimed
US-20040063658-A1 Nucleoside derivatives for treating hepatitis C virus infection GENELABS TECHNOLOGIES, INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063658-A1 Nucleoside derivatives for treating hepatitis C virus infection HAVCR2, PNP, NTPCR ADORA2A 174/4885ADA 13/4885ADORA3 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.